



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/573, 9/22, A61P 27/02	A1	(11) International Publication Number: WO 00/56340 (43) International Publication Date: 28 September 2000 (28.09.00)
(21) International Application Number: PCT/US00/07513 (22) International Filing Date: 22 March 2000 (22.03.00) (30) Priority Data: 09/273,548 22 March 1999 (22.03.99) US (71) Applicant: CONTROL DELIVERY SYSTEMS [US/US]; 86 Rosedale Road, Watertown, MA 02172 (US). (72) Inventors: GUO, Hong; 50 Sandrick Road, Belmont, MA 02478 (US). ASHTON, Paul; 19 Brimmer Street #5, Boston, MA 02114 (US). (74) Agents: KRAUS, Eric, J. et al.; McDermott, Will & Emery, 600 13th Street, N.W., Washington, DC 20005-3096 (US).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: METHOD FOR TREATING AND/OR PREVENTING RETINAL DISEASES WITH SUSTAINED RELEASE CORTICOSTEROIDS (57) Abstract The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHOD FOR TREATING AND/OR PREVENTING RETINAL
DISEASES WITH SUSTAINED RELEASE CORTICOSTEROIDS

Field Of The Invention

The present invention relates to the field of controlled pharmaceutical delivery, particularly to corticosteroids.

Background Of The Invention

5 Compounds classified as corticosteroids, such as triamcinolone, effectively treat neovascularization and a number of other diseases including age related macular degeneration. In many patients, however, these compounds cause undesirable side effects. These adverse affects include elevations in intraocular pressure and the formation of, or acceleration of, the development of cataracts. Elevations in intraocular pressure are of particular concern in
10 patients who are already suffering from elevated intraocular pressure, such as glaucoma patients. Moreover, a risk exists that the use of corticosteroids in patients with normal intraocular pressure will cause elevations in pressure that result in damage to ocular tissue. Since therapy with corticosteroids is frequently long term, i.e., several days or more, a potential exists for significant damage to ocular tissue as a result of prolonged elevations in
15 intraocular pressure attributable to that therapy.

One approach to solving the foregoing problems has been to search for specific compounds which are effective without elevating intraocular pressure. Another approach has been to administer glucocorticoids in conjunction with another drug to "block" or reduce the IOP elevating effects of the glucocorticoid or to treat IOP elevation separately with another
20 drug. A further approach has been to intravitreally inject corticosteroids to treat ocular neovascularization.

There exists a need for an improved method for treating and/or preventing retinal diseases with corticosteroids.

Disclosure of the Invention

25 An object of the present invention is to provide a method for treating and/or preventing ocular neovascularization with corticosteroids without the associated adverse side effects.

Additional objects, advantages and other features of the invention will be set forth in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from the practice of the invention. The objects and advantages of the invention may be realized and obtained as particularly pointed out in the appended claims.

According to the present invention, the foregoing and other objects are achieved in part by a method for administering a corticosteroid to a posterior segment of an eye, the method comprising the step of:

implanting a sustained release device to deliver the corticosteroid to the vitreous of the eye wherein aqueous corticosteroid concentration is less than vitreous corticosteroid concentration during release.

In accordance with the present invention, the foregoing and other advantages are also achieved in part by an implantable, sustained release device for administering a corticosteroid to a posterior segment of an eye, the device comprising:

a corticosteroid, wherein the device is configured to provide sustained release of the corticosteroid to the vitreous of the eye such that aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during the release.

Additional objects and advantages of the present invention will become readily apparent to those skilled in this art from the following detailed description, wherein embodiments of the invention are described simply by way of illustrating of the best mode contemplated in carrying out the invention. As will be realized, the invention is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the invention. Accordingly, the drawings and description are to be regarded as illustrative in nature and not as restrictive.

Brief Description of Drawings

Fig. 1 shows the sustained release profile of a 2 mg fluocinolone acetonide implant in buffer.

Fig 2. shows the vitreous and aqueous levels of fluocinolone acetonide after implantation of a sustained release device.

Description of the Invention

The present invention provides a method for administering a corticosteroid to the vitreous of an eye. The method comprises the step of implanting a sustained release device comprising a corticosteroid to deliver the corticosteroid to the vitreous wherein aqueous

corticosteroid concentration is less than vitreous corticosteroid concentration during release of the corticosteroid.

The present invention is particularly effective in treating retinal diseases. Retinal diseases include, for example, ocular neovascularization, ocular inflammation and retinal degeneration. Specific examples of these disease states include diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, senile macular degeneration due to subretinal neovascularization); rubeosis iritis inflammatory diseases, chronic posterior and pan uveitis, neoplasms (retinoblastoma, pseudoglioma); neovascular glaucoma; neovascularization resulting following a combined vitrectomy and lensectomy; vascular diseases (retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis); neovascularization of the optic nerve; diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, and retinal artery occlusion; and, neovascularization due to penetration of the eye or ocular injury.

Examples of corticosteroids useful in the present invention include, for example, triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

By "sustained release device" it is meant a device that releases drug over an extended period of time in a controlled fashion. Examples of sustained release devices useful in the present invention may be found in, for example, U.S. Patent No. 5,378,475 and U.S. Patent No. 5,773,019, and U.S. Serial No. 08/919,221 filed on August 28, 1997.

By "vitreous" of the eye, it is meant the vitreous or vitreal cavity of the eye. By "aqueous" of the eye, it is meant the aqueous humor of the eye.

In the present invention, a sustained release device is implanted into the eye such that it delivers corticosteroid to the posterior segment of the eye. In a preferred embodiment, the sustained release device is implanted intravitreally. However, the device may also be implanted in the choroidal space, sub-retinally, or in the sclera. These methods of administration and techniques for their preparation are well known by those of ordinary skill in the art. Methods of administration and techniques for their preparation are set forth in Remington's Pharmaceutical Sciences.

The aqueous corticosteroid concentration remains less than the vitreous corticosteroid concentration for substantially the lifetime of the sustained release device. Thus, during release of the corticosteroid, the aqueous corticosteroid concentration is about 0.002 $\mu\text{g/ml}$ to about 0.01 $\mu\text{g/ml}$, such as from about 0.01 $\mu\text{g/ml}$ to about 0.02 $\mu\text{g/ml}$. Preferably, the aqueous corticosteroid concentration is less than about 0.02 $\mu\text{g/ml}$.

In contrast, during release of the corticosteroid, the vitreous corticosteroid concentration remains therapeutic, that is, less than about 10 $\mu\text{g/ml}$. The exact concentration depends upon the disease and therapeutic index of the drug.

The sustained release device useful in the present invention is any device which can be implanted to deliver corticosteroid to the vitreous of the eye and can release a corticosteroid for a sustained period of time, that is, for about 1 month to about 20 years, such as from about 6 months to about 5 years.

5 The sustained release device can be prepared to release the corticosteroid by pseudo zero order kinetics with a mean release rate of about 1 $\mu\text{g/day}$ to about 50 $\mu\text{g/day}$, such as, about 1 $\mu\text{g/day}$ to about 10 $\mu\text{g/day}$.

The following non-limiting examples are given by way of illustration only.

Example 1

10 Sustained release fluocinolone acetonide devices were implanted into the vitreous of 4 rabbits while animals in the control group received a sham operation. After implantation, all rabbits received a sub-retinal injection of gelatin microspheres releasing basic fibroblast growth factor. All control animals developed neovascularization while 3/4 of the implant group showed no evidence of neovascularization. No animals showed any indication of
15 ocular or systemic steroid-induced toxicity.

Example 2

Animals received intravitreal fluocinolone acetonide implants and were sacrificed at 1 month, 4 months, and 11 months. Samples of the vitreous and aqueous were collected for analysis by HPLC. Analysis was performed using a fully automated Hitachi HPLC system.
20 The mobile phase was 40% acetonitrile buffered to a pH of 4.0. The flow rate was 1.0 ml/min with an Axxion C-18 column (25cm X 4mm X 5 μm) and UV detection at 238nm. Intravitreal levels were found to be relatively constant throughout the study (0.1-0.2 $\mu\text{g/ml}$) while no steroid was detected in the aqueous humor (limit of detection 0.02 $\mu\text{g/ml}$).

Detailed Description of the Drawings

25 Fig. 1 shows the sustained release profile of a 2 mg flucinolone acetonide implant in buffer over 100 days. The mean release rate was 2.1 \pm 0.26 $\mu\text{g/day}$.

Fig. 2 shows the vitreous and aqueous levels of fluocinolone acetonide after implantation of a sustained release device. Animals were sacrificed at 1 month, 3 months, and 1 year. Fig. 2 shows that therapeutic levels are maintained in the vitreous while drug levels in
30 the aqueous humor were below the detection limit of the assay.

In the previous descriptions, numerous specific details are set forth, such as specific materials, structures, chemicals, processes, etc., in order to provide a better understanding of the present invention. However, the present invention can be practiced without resorting to

the details specifically set forth. In other instances, well-known processing structures have not been described in detail in order not to unnecessarily obscure the present invention.

5 Only the preferred embodiment of the invention and but a few examples of its versatility are shown and described in the present disclosure. It is to be understood that the present invention is capable of use in various other combinations and environments and is capable of changes or modifications within the scope of the inventive concept as expressed herein. All patents, patent applications and publication cited herein are incorporated by reference in their entirety.

What is claimed is:

1. A method for administering a corticosteroid to a posterior segment of an eye, the method comprising the step of:
implanting a sustained release device to deliver the corticosteroid to the vitreous of the eye and wherein aqueous corticosteroid concentration is less than vitreous corticosteroid concentration during release.
2. A method according to claim 1, wherein aqueous corticosteroid concentration is about 0.002 $\mu\text{g/ml}$ to about 0.01 $\mu\text{g/ml}$.
3. A method according to claim 2, wherein aqueous corticosteroid concentration is about 0.01 $\mu\text{g/ml}$ to about 0.02 $\mu\text{g/ml}$.
4. A method according to claim 1, wherein aqueous corticosteroid concentration is less than 0.02 $\mu\text{g/ml}$.
5. A method according to claim 1, wherein the device releases corticosteroid for about 1 month to about 10 years.
6. A method according to claim 5, wherein the device releases corticosteroid for about 6 months to about 5 years
7. A method according to claim 1, wherein the vitreous corticosteroid concentration is therapeutic.
8. A method according to claim 1, wherein the vitreous corticosteroid concentration is less than about 10 $\mu\text{g/ml}$.
9. A method according to claim 1, wherein the corticosteroid is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.
10. A method according to claim 1, comprising intravitreally implanting the sustained release device.
11. A method according to claim 1, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

12. A method according to claim 1, wherein the sustained release device releases the corticosteroid with pseudo zero order kinetics.
13. A method according to claim 1, wherein the sustained release device has a mean release rate of about 1 $\mu\text{g/day}$ to about 50 $\mu\text{g/day}$ of corticosteroid.
14. A method according to claim 13, wherein sustained release device has a mean release rate of about 1 $\mu\text{g/day}$ to about 10 $\mu\text{g/day}$ of corticosteroid.
15. A method according to claim 1, wherein the sustained release device releases only one drug.
16. An implantable, sustained release device for administering a corticosteroid to a posterior segment of an eye, the device comprising:
a corticosteroid, wherein the device is configured to provide sustained release of the corticosteroid to the vitreous of the eye such that aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during the release.

5

1/2




FIG. 1

2/2




FIG. 2

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/07513

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/573 A61K9/22 A61P27/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 11244 A (CONTROL DELIVERY SYSTEMS, INC.) 11 March 1999 (1999-03-11) cited in the application page 12, line 15 - line 21 page 26, line 10 - line 20	1-16

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

23 August 2000

Date of mailing of the international search report

30/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 00/07513

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9911244 A	11-03-1999	US 5902598 A	11-05-1999
		AU 9029198 A	22-03-1999
		EP 1009388 A	21-06-2000
		NO 20000735 A	28-04-2000